ibalizumab

Known as: Immunoglobulin G4, Anti-(Human CD4 (Antigen)) (Human-Mouse Monoclonal 5A8 Gamma-4-Chain), Disulfide with Human-Mouse Monoclonal 5A8 Kappa-Chain, Dimer 
A humanized monoclonal antibody against CD4, with anti-human immunodeficiency virus (HIV) activity. Ibalizumab binds to CD4, the primary receptor for… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2017
024620072017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing evaluation in late-stage clinical studies… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
OBJECTIVES Passive immunization for the prevention of HIV-1 infection is currently being reenergized. The anti-CD4 monoclonal… (More)
Is this relevant?
2013
2013
In the absence of an effective HIV-1 vaccine, passive immunization using broadly neutralizing Abs or Ab-like molecules could… (More)
Is this relevant?
2013
2013
BMS-626529 is a novel small-molecule HIV-1 attachment inhibitor active against both CCR5- and CXCR4-tropic viruses. BMS-626529… (More)
Is this relevant?
2011
2011
Ibalizumab (formerly TNX-355) is a first-in-class, monoclonal antibody inhibitor of CD4-mediated human immunodeficiency type 1… (More)
  • figure 2
  • figure 1
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2010
2010
The majority of currently available agents for the treatment of HIV-1 infection act by targeting one of several intracellular… (More)
  • table 1
Is this relevant?
2010
2010
Ibalizumab is a humanized monoclonal antibody that binds human CD4, the primary receptor for human immunodeficiency virus type 1… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Ibalizumab is a humanized, anti-CD4 monoclonal antibody. It potently blocks HIV-1 infection and targets an epitope in the second… (More)
Is this relevant?
2009
2009
Ibalizumab (formerly TNX-355) is a humanized monoclonal antibody that binds CD4, the primary receptor for human immunodeficiency… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Review
2007
Review
2007
Tanox Inc (under license from Biogen Idec, formerly Biogen Inc) is developing ibalizumab, an intravenous, humanized, monoclonal… (More)
Is this relevant?